Search research articles
Contact Us
Filters
Showing results (191-200 of 245) with videos related to
Page
of 25
Sort By:
Hepatology (Baltimore, Md.)
|
October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
Mark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Bone Research
|
January 28, 2022
Procalcitonin is expressed in osteoblasts and limits bone resorption through inhibition of macrophage migration during intermittent PTH treatment
Anke Baranowsky, Denise Jahn, Shan Jiang, et al.
Alimentary Pharmacology & Therapeutics
|
May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
S C Gordon, E M Yoshida, E J Lawitz, et al.
Gastroenterology
|
March 23, 2011
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
Jordi Bruix, Thierry Poynard, Massimo Colombo, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 16, 2008
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators
Brian K Albrecht, Virginia Berry, Alessandro A Boezio, et al.
Gastroenterology
|
August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
Mark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
JCI Insight
|
August 13, 2016
Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation
Kong Chen, Brian T Campfield, Sally E Wenzel, et al.
Journal of Viral Hepatitis
|
March 13, 2012
Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin
D A Kelly, B Haber, R P González-Peralta, et al.
Leukemia
|
August 1, 2017
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
E Hadzijusufovic, K Albrecht-Schgoer, K Huber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
Steven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 245) with videos related to
Sort By:
Page
of 25
Hepatology (Baltimore, Md.)
|
October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
Mark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Bone Research
|
January 28, 2022
Procalcitonin is expressed in osteoblasts and limits bone resorption through inhibition of macrophage migration during intermittent PTH treatment
Anke Baranowsky, Denise Jahn, Shan Jiang, et al.
Alimentary Pharmacology & Therapeutics
|
May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
S C Gordon, E M Yoshida, E J Lawitz, et al.
Gastroenterology
|
March 23, 2011
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
Jordi Bruix, Thierry Poynard, Massimo Colombo, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 16, 2008
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators
Brian K Albrecht, Virginia Berry, Alessandro A Boezio, et al.
Gastroenterology
|
August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
Mark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
JCI Insight
|
August 13, 2016
Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation
Kong Chen, Brian T Campfield, Sally E Wenzel, et al.
Journal of Viral Hepatitis
|
March 13, 2012
Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin
D A Kelly, B Haber, R P González-Peralta, et al.
Leukemia
|
August 1, 2017
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
E Hadzijusufovic, K Albrecht-Schgoer, K Huber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
Steven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Page
of 25